CGTX Plunges 10.66% Despite FDA Boost

Cognition Therapeutics, Inc. (CGTX) experienced a significant drop of 10.66% in pre-market trading on August 14, 2025.

Cognition Therapeutics, Inc. has been downgraded to a Buy Candidate from a Strong Buy, reflecting a weaker technical forecast. The stock has shown a strong upward trend in the short term, but recent signals indicate potential selling opportunities. The stock is expected to rise 147.65% over the next three months, with a 90% probability of holding a price between $1.59 and $2.75.

Despite the downgrade, several short-term signals and a general positive trend suggest that the current level may still present a buying opportunity. The stock has support levels at $0.86 and $0.84, which could act as a safety net in case of further declines. The stock's movements are generally controlled, indicating a low risk, but investors should remain vigilant, especially during periods of low or falling volume.

Cognition Therapeutics' stock price surge was driven by the FDA's confirmation that its Phase 3 program for zervimesine (CT1812) can proceed under a fast-tracked design. This development has significantly boosted investor confidence in the company's prospects. Additionally, the company has received End-of-Phase 2 Meeting Minutes confirming alignment with the U.S. FDA on the registrational path for zervimesine in Alzheimer's disease, further validating its clinical progress.